-

SHAREHOLDER ALERT: Robbins LLP Investigates Embark Technology, Inc. (EMBK) on Behalf of Shareholders

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP is investigating Embark Technology, Inc. (NASDAQ: EMBK) to determine whether certain Embark officers and directors violated securities laws and breached fiduciary duties to shareholders. Embark describes itself as "an autonomous vehicle company building the software powering autonomous trucks."

If you would like more information about our investigation of Embark Technology, Inc.'s misconduct, click here.

Embark Technology, Inc. (EMBK) Criticized as Being "More Bark than Bite"

On January 1, 2022, The Bear Cave released report entitled "Problems at Embark Technology," stating, “Embark’s current valuation appears to be based on puffery rather than actual substance. The company holds no patents, has only a dozen or so test trucks, and may be more bark than bite.” Further, The Bear Cave reported that “[m]ore troubling is that Embark appears to lack true economic substance.” Following this news, Embark’s stock price plummeted 16%.

Embark Technology, Inc. (EMBK) shareholders have legal options. If you own shares of Embark Technology, Inc., contact us for more information about your rights.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

Contact us to learn more:

Aaron Dumas
(800) 350-6003
adumas@robbinsllp.com
Shareholder Information Form

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against Embark Technology, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Aaron Dumas
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Simulation Plus, Inc. (NASDAQ: SLP) Investors Should Contact Robbins LLP for Information About Investigation

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP announces that it is investigating Simulation Plus, Inc. (NASDAQ: SLP) to determine whether certain officers and directors violated securities laws or breached fiduciary duties owed to shareholdersThe investigation concerns whether Simulation Plus made materially false or misleading statements or omitted material information regarding its financial reporting, internal controls, and business outlook.Investors who purchased Simulation Plus securities and suf...

Acadia Healthcare (NASDAQ: ACHC) Investors: Court Denies Motion to Dismiss Paving Way for Litigation to Proceed; Contact Robbins LLP for Information About Your Rights

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds investors of their rights following the court's decision to allow securities claims against Acadia Healthcare Company (NASDAQ: ACHC) to proceed.The case is continuing after the Court denied defendants’ motion to dismiss the amended complaint. The ruling means the case can proceed past the motion-to-dismiss stage. It does not determine whether the allegations are true or establish liability. Investors who purchased or otherwise acquired Acadia Healt...

Insulet Corporation (NASDAQ: PODD) Investors Who Suffered Losses May Be Eligible to Participate in Securities Class Action; Contact Robbins LLP for Information About Recovering Your Losses

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds investors that a securities class action has been filed on behalf of all persons and entities that purchased or otherwise acquired Insulet Corporation (NASDAQ: PODD) securities between February 21, 2025 and May 26, 2026, inclusive (the "Class Period"). The lawsuit alleges that Insulet made materially false or misleading statements regarding its manufacturing controls and the safety and reliability of its insulin delivery products. Investors who su...
Back to Newsroom